Rizzo A.; Mollica V.; Dall'Olio F.G.; Ricci A.D.; Maggio I.; Marchetti A.; Rosellini M.; Santoni M.; Ardizzoni A.; Massari F., Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review, «FUTURE ONCOLOGY», 2021, 17, pp. 2671 - 2681 [Scientific article]
Rizzo A.; Dall'Olio F.G.; Altimari A.; Giunchi F.; Ardizzoni A., Role of PD-L1 assessment in advanced NSCLC: does it still matter?, «ANTI-CANCER DRUGS», 2021, 32, pp. 1084 - 1085 [Scientific article]
Federico, Alessandro Di; Gelsomino, Francesco; De Biase, Dario; Ardizzoni, Andrea, Should We Test Cancer Susceptibility Genes in Routinely Used Multigene Panels? A Case of Synchronous Lung Adenocarcinoma and Breast Cancer Associated With Germline CHEK2 Mutation, «CLINICAL LUNG CANCER», 2021, 000, pp. 1 - 2 [Scientific article]
Di Federico A.; Andrini E.; Sisi M.; Nuvola G.; Lamberti G.; Lenzi B.; Nobili E.; Gelsomino F.; Ardizzoni A., Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution, «ANTI-CANCER DRUGS», 2021, 32, pp. 755 - 757 [Scientific article]Open Access
Apolone, G.; Ardizzoni, A.; Biondi, A.; Bortolami, A.; Cardone, C.; Ciniselli, C.M.; Conte, P.; Crippa, C.; de Braud, F.; Duca, M.; Gori, S.; Gritti, G.; Inno, A.; Luksch, R.; Lussana, F.; Maio, M.; Pasello, G.; Perrone, F.; Rambaldi, A.; Rossi, G.; Signorelli, D.; Soverini, G.; Valente, M.; Verderio, P.; Buzzetti, G., Skip pattern approach toward the early access of innovative anticancer drugs, «ESMO OPEN», 2021, 6, Article number: 100227 , pp. 1 - 8 [Scientific article]Open Access
Dingemans A.-M.C.; Fruh M.; Ardizzoni A.; Besse B.; Faivre-Finn C.; Hendriks L.E.; Lantuejoul S.; Peters S.; Reguart N.; Rudin C.M.; De Ruysscher D.; Van Schil P.E.; Vansteenkiste J.; Reck M., Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆, «ANNALS OF ONCOLOGY», 2021, 32, pp. 839 - 853 [Scientific article]Open Access
Francesca Coppola, Margherita Mottola, Silvia Lo Monaco, Arrigo Cattabriga, Maria Adriana Cocozza, Jia Cheng Yuan, Caterina De Benedittis, Dajana Cuicchi, Alessandra Guido, Fabiola Lorena Rojas Llimpe, Antonietta D’Errico, Andrea Ardizzoni, Gilberto Poggioli, Lidia Strigari, Alessio Giuseppe Morganti, Franco Bazzoli, Luigi Ricciardiello, Rita Golfieri, Alessandro Bevilacqua, The Heterogeneity of Skewness in T2W-Based Radiomics Predicts the Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer, «DIAGNOSTICS», 2021, 11, Article number: 795 , pp. 1 - 13 [Scientific article]Open Access
Raschi, Emanuel; Fusaroli, Michele; Ardizzoni, Andrea; Poluzzi, Elisabetta; De Ponti, Fabrizio, Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System, «CANCERS», 2021, 13, Article number: 1758 , pp. 1 - 12 [Scientific article]Open Access
Tarricone R.; Listorti E.; Tozzi V.; Torbica A.; Banks H.; Ghislandi S.; Altini M.; Annicchiarico M.; Ardizzoni A.; Bordon P.; Bossi P.; Cascinu S.; Numico G.; Puglisi F.; Fasola G., Transformation of Cancer Care during and after the COVID Pandemic, a point of no return. The Experience of Italy, «JOURNAL OF CANCER POLICY», 2021, 29, Article number: 100297 , pp. 1 - 5 [Scientific article]Open Access
Taronna G.; Leonetti A.; Gustavo Dall'Olio F.; Rizzo A.; Parisi C.; Buti S.; Bordi P.; Brocchi S.; Golfieri R.; Ardizzoni A.; Sverzellati N.; Tiseo M., Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib, «TUMORI», 2021, 00(0), pp. 1 - 8 [Scientific article]
Mollica V.; Brocchi S.; Dall'olio F.G.; Marcolin L.; Paccapelo A.; Santoni M.; Rizzo A.; Montironi R.; Golfieri R.; Massari F.; Ardizzoni A., Tumor growth rate decline despite progressive disease may predict improved nivolumab treatment outcome in mrcc: When recist is not enough, «CANCERS», 2021, 13, Article number: 3492 , pp. 1 - 10 [Scientific article]Open Access
Morgensztern D.; Dols M.C.; Ponce Aix S.; Postmus P.E.; Bennouna J.; Fischer J.R.; Juan-Vidal O.; Stewart D.J.; Ardizzoni A.; Bhore R.; Wolfsteiner M.; Reck M.; Talbot D.; Govindan R.; Ong T.J., nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+), «FRONTIERS IN ONCOLOGY», 2021, 10, Article number: 569715 , pp. 1 - 9 [Scientific article]Open Access
Massucci, Maria; Di Fabio, Francesca; Rojas Llimpe, Fabiola L; Ardizzoni, Andrea, A Case of Response to Immunotherapy in a Patient With MSI Metastatic Colorectal Cancer and Autoimmune Disease in Steroid Therapy, «JOURNAL OF IMMUNOTHERAPY», 2020, 43, pp. 153 - 155 [Scientific article]
Vitale G.; Lamberti G.; Comito F.; Di Nunno V.; Massari F.; Morelli M.C.; Ardizzoni A.; Gelsomino F., Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience, «EXPERT OPINION ON BIOLOGICAL THERAPY», 2020, 20, pp. 1047 - 1059 [Scientific article]
Gelsomino F.; Lamberti G.; Tiseo M.; Rocco D.; Pasello G.; Cecere F.L.; Chella A.; Grilli G.; Mandruzzato M.; Tognetto M.; Garassino M.C.; Macerelli M.; Novello S.; Roila F.; Colantonio I.; Grossi F.; Fiorentino M.; Ardizzoni A., Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial), «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY», 2020, 12, pp. 1 - 6 [Scientific article]Open Access
